LABP Key Statistics, Chart & Performance
The current stock price of LABP is 22.93 USD. In the past month the price increased by 1.96%. In the past year, price increased by 693.43%.
LABP Latest News, Press Relases and Analysis
LABP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.19 | 1.00T | ||
| JNJ | JOHNSON & JOHNSON | 19.64 | 491.06B | ||
| MRK | MERCK & CO. INC. | 11.1 | 244.18B | ||
| PFE | PFIZER INC | 7.82 | 142.37B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.05 | 94.14B | ||
| ZTS | ZOETIS INC | 19.25 | 54.09B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.47 | 22.70B | ||
| VTRS | VIATRIS INC | 4.49 | 12.20B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.18 | 11.05B | ||
| CORT | CORCEPT THERAPEUTICS INC | 87.83 | 8.14B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.46B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.04B |
Related stock screener links
About LABP
Company Profile
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of novel, oral, once-daily therapeutics for patients with certain immunology diseases. The company is headquartered in Blacksburg, Virginia and currently employs 22 full-time employees. The company went IPO on 2021-02-04. The company is engaged in the clinical development of compounds that target pathways at the interface of immunity and metabolism. Its lead candidate is NX-13, an oral, gut-selective NLRX1 agonist. The company is developing NX-13 as a once-daily oral treatment for ulcerative colitis (UC) that targets the NOD-like receptor X1 (NLRX1), a mitochondria-associated receptor that has been associated with the modulation of inflammatory cytokines in UC. NX-13 is designed to target NLRX1 and induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. In addition to NX-13, it has discovered several preclinical product candidates, such as LABP-73, LABP-66 and LABP-69. LABP-73, an oral, small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease.
Company Info
LANDOS BIOPHARMA INC
1800 Kraft Drive, Suite 216
Blacksburg VIRGINIA 24060 US
CEO: Josep Bassaganya-Riera
Employees: 22
Phone: 15408182844
LANDOS BIOPHARMA INC / LABP FAQ
Can you describe the business of LANDOS BIOPHARMA INC?
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of novel, oral, once-daily therapeutics for patients with certain immunology diseases. The company is headquartered in Blacksburg, Virginia and currently employs 22 full-time employees. The company went IPO on 2021-02-04. The company is engaged in the clinical development of compounds that target pathways at the interface of immunity and metabolism. Its lead candidate is NX-13, an oral, gut-selective NLRX1 agonist. The company is developing NX-13 as a once-daily oral treatment for ulcerative colitis (UC) that targets the NOD-like receptor X1 (NLRX1), a mitochondria-associated receptor that has been associated with the modulation of inflammatory cytokines in UC. NX-13 is designed to target NLRX1 and induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. In addition to NX-13, it has discovered several preclinical product candidates, such as LABP-73, LABP-66 and LABP-69. LABP-73, an oral, small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease.
What is the stock price of LANDOS BIOPHARMA INC today?
The current stock price of LABP is 22.93 USD. The price increased by 0.58% in the last trading session.
Does LABP stock pay dividends?
LABP does not pay a dividend.
How is the ChartMill rating for LANDOS BIOPHARMA INC?
LABP has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of LABP stock?
LANDOS BIOPHARMA INC (LABP) operates in the Health Care sector and the Pharmaceuticals industry.
What is the employee count for LABP stock?
LANDOS BIOPHARMA INC (LABP) currently has 22 employees.
What is the market capitalization of LABP stock?
LANDOS BIOPHARMA INC (LABP) has a market capitalization of 71.77M USD. This makes LABP a Micro Cap stock.
LABP Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to LABP. When comparing the yearly performance of all stocks, LABP is one of the better performing stocks in the market, outperforming 99.88% of all stocks.
LABP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LABP. No worries on liquidiy or solvency for LABP as it has an excellent financial health rating, but there are worries on the profitability.
LABP Financial Highlights
Over the last trailing twelve months LABP reported a non-GAAP Earnings per Share(EPS) of -3.99. The EPS increased by 43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.94% | ||
| ROE | -107.09% | ||
| Debt/Equity | 0 |
LABP Forecast & Estimates
8 analysts have analysed LABP and the average price target is 12.96 USD. This implies a price decrease of -43.46% is expected in the next year compared to the current price of 22.93.